Sarepta Therapeutics announced a strategic restructuring plan involving a 36% workforce reduction of approximately 500 employees, following safety concerns associated with its gene therapy Elevidys for Duchenne muscular dystrophy (DMD). The FDA has requested a black box warning for acute liver injury risks linked to Elevidys after two patient deaths. Sarepta has paused Elevidys shipments to non-ambulatory patients and is developing enhanced immunosuppression regimens for liver toxicity management. The company is pivoting its pipeline focus toward siRNA-based therapies for rare genetic diseases, aiming to achieve annual cost savings of about $400 million and ensure fiscal stability through 2027.